- Although beta-blocker use at the time of NSCLC diagnosis was not associated with lung cancer-specific mortality overall, there was a slight association between propranolol and increased lung cancer-specific mortality.
Why this matters
- Previous studies had suggested a possible link between beta-blockers and a decreased risk for lung cancer-specific mortality.
- 18,429 patients with NSCLC from the Swedish Cancer Register.
- Funding: Swedish Cancer Society.
- 28% were beta-blocker users, 45% of whom were high-dose users.
- Metoprolol was the most common beta-blocker.
- Most common indications for beta-blockers were hypertension (61%) and heart disease (59%).
- Overall, there was no significant association between beta-blocker use and lung cancer-specific mortality, regardless of tumor stage or beta-blocker solubility or dose.
- However, there was a slight association between propranolol and lung cancer-specific mortality (HR, 1.22; 95% CI, 1.03-1.45).
- Similar results were found after propensity matching.
- Retrospective study.